Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis

References

• Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5(Suppl 4):S1-6
   Google Scholar
• Wilson CL, Hine DW, Pradipta A, et al. Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation. Immunology 2012;135(4):344-54
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7(6):429-42
   PubMed Web of Science ®Google Scholar
• Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205-19
   PubMed Web of Science ®Google Scholar
• Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004;172(2):803-11
   Google Scholar
• Bosma A, Abdel-Gadir A, Isenberg DA, et al. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012;36(3):477-90
   PubMed Web of Science ®Google Scholar
• Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013;210(3):445-55
   PubMed Web of Science ®Google Scholar
• Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012;8(10):573-86
   PubMed Web of Science ®Google Scholar
• Diogo D, Kurreeman F, Stahl EA, et al. Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis. Am J Hum Genet 2013;92(1):15-27
   Google Scholar
• Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014;506(7488):376-81
   PubMed Web of Science ®Google Scholar
• Klareskog L, Malmstrom V, Lundberg K, et al. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011;23(2):92-8
   PubMedGoogle Scholar
• Haj Hensvold A, Magnusson PK, Joshua V, et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, et al. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum 2013;65(1):69-80
   PubMed Web of Science ®Google Scholar
• Romero V, Fert-Bober J, Nigrovic PA, et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med 2013;5:209):209ra150.
   Google Scholar
• Bojalil R, Mazon-Gonzalez B, Carrillo-Cordova JR, et al. Frequency and clinical significance of a variety of autoantibodies in patients with definite infective endocarditis. J Clin Rheumatol 2012;18(2):67-70
   Google Scholar
• Charles ED, Orloff MI, Nishiuchi E, et al. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2013;65(9):2430-40
   Google Scholar
• Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171(2):538-41
   PubMed Web of Science ®Google Scholar
• Elliott MR, Ravichandran KS. Clearance of apoptotic cells: implications in health and disease. J Cell Biol 2010;189(7):1059-70
   PubMed Web of Science ®Google Scholar
• Law SC, Street S, Yu CH, et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012;14(3):R118
   PubMed Web of Science ®Google Scholar
• Uysal H, Bockermann R, Nandakumar KS, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009;206(2):449-62
   Google Scholar
• Young KA, Deane KD, Derber LA, et al. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum 2013;65(8):1995-2004
   Google Scholar
• Barra L, Scinocca M, Saunders S, et al. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. Arthritis Rheum 2013;65(6):1439-47
   PubMedGoogle Scholar
• Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011;13(1):R13
   PubMed Web of Science ®Google Scholar
• Suwannalai P, Willemze A, van Toorn L, et al. The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. Arthritis Res Ther 2011;13(6):R195
   Google Scholar
• Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PloS One 2012;7(5):e35296
   PubMed Web of Science ®Google Scholar
• van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69(8):1554-61
   PubMed Web of Science ®Google Scholar
• Rombouts Y, Ewing E, van de Stadt LA, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• Kinloch A, Lundberg K, Wait R, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008;58(8):2287-95
   PubMed Web of Science ®Google Scholar
• Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Science Transl Med 2013;5(178):178ra140
   Web of Science ®Google Scholar
• Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001;167(3):1601-8
   PubMed Web of Science ®Google Scholar
• Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011;108(42):17372-7
   PubMed Web of Science ®Google Scholar
• Mydel P, Wang Z, Brisslert M, et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010;184(12):6882-90
   PubMed Web of Science ®Google Scholar
• de Vries RR, van der Woude D, Houwing JJ, et al. Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end? Ann Rheum Dis 2011;70(Suppl 1):i51-4
   Google Scholar
• Sokolove J, Zhao X, Chandra PE, et al. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011;63(1):53-62
   PubMedGoogle Scholar
• Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013;210(12):2569-82
   PubMed Web of Science ®Google Scholar
• Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16(2):157-68
   PubMed Web of Science ®Google Scholar
• Cantaert T, Kolln J, Timmer T, et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008;181(1):785-94
   PubMed Web of Science ®Google Scholar
• Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009;6(1):e1
   PubMed Web of Science ®Google Scholar
• Rosengren S, Wei N, Kalunian KC, et al. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008;10(5):R105
   Google Scholar
• van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70(5):772-7
   Web of Science ®Google Scholar
• Kendall PL, Yu G, Woodward EJ, et al. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J Immunol 2007;178(9):5643-51
   PubMed Web of Science ®Google Scholar
• Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010;22(3):307-15
   Google Scholar
• Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 2011;11(1):34-46
   PubMed Web of Science ®Google Scholar
• Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013;13(2):118-32
   PubMed Web of Science ®Google Scholar
• Kearney JF. Innate-like B cells. Springer Semin Immunopathol 2005;26(4):377-83
   Google Scholar
• Guerrier T, Youinou P, Pers JO, et al. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J Autoimmun 2012;39(3):173-9
   PubMed Web of Science ®Google Scholar
• Oliver AM, Martin F, Gartland GL, et al. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 1997;27(9):2366-74
   Google Scholar
• You Y, Myers RC, Freeberg L, et al. Marginal zone B cells regulate antigen capture by marginal zone macrophages. J Immunol 2011;186(4):2172-81
   Web of Science ®Google Scholar
• Cinamon G, Zachariah MA, Lam OM, et al. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008;9(1):54-62
   PubMed Web of Science ®Google Scholar
• Eto D, Lao C, DiToro D, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PloS One 2011;6(3):e17739
   PubMed Web of Science ®Google Scholar
• Wurster AL, Rodgers VL, White MF, et al. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002;277(30):27169-75
   PubMed Web of Science ®Google Scholar
• Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010;42(6):508-14
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010;1183:38-57
   PubMed Web of Science ®Google Scholar
• Ray A, Basu S, Williams CB, et al. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol 2012;188(7):3188-98
   PubMed Web of Science ®Google Scholar
• Yang M, Deng J, Liu Y, et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol 2012;180(6):2375-85
   PubMed Web of Science ®Google Scholar
• Maseda D, Smith SH, DiLillo DJ, et al. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol 2012;188(3):1036-48
   Google Scholar
• Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013;5:173):173ra123.
   Web of Science ®Google Scholar
• Ma L, Liu B, Jiang Z, et al. Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Rheumatol 2014;33(2):187-95
   PubMed Web of Science ®Google Scholar
• Wilde B, Thewissen M, Damoiseaux J, et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013;72(8):1416-19
   PubMed Web of Science ®Google Scholar
• Vadasz Z, Haj T, Kessel A, et al. B-regulatory cells in autoimmunity and immune mediated inflammation. FEBS Lett 2013;587(13):2074-8
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol 2009;155(1):1-15
   PubMed Web of Science ®Google Scholar
• Shulzhenko N, Morgun A, Hsiao W, et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med 2011;17(12):1585-93
   PubMed Web of Science ®Google Scholar
• Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013;13(5):321-35
   PubMed Web of Science ®Google Scholar
• Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32(6):815-27
   PubMed Web of Science ®Google Scholar
• Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013;2:e01202
   PubMed Web of Science ®Google Scholar
• Chervonsky AV. Influence of microbial environment on autoimmunity. Nat Immunol 2010;11(1):28-35
   Google Scholar
• Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012;336(6086):1268-73
   PubMed Web of Science ®Google Scholar
• Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One 2007;2(9):e863
   Google Scholar
• Genestier L, Taillardet M, Mondiere P, et al. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 2007;178(12):7779-86
   PubMed Web of Science ®Google Scholar
• Boeglin E, Smulski CR, Brun S, et al. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells. PLoS One 2011;6(10):e25542
   Google Scholar
• Dorner M, Brandt S, Tinguely M, et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009;128(4):573-9
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416(6881):603-7
   PubMed Web of Science ®Google Scholar
• Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology 2012;51(1):7-23
   PubMed Web of Science ®Google Scholar
• Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010;88(2):253-62
   PubMed Web of Science ®Google Scholar
• Lu J, Teh C, Kishore U, et al. Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system. Biochim Biophys Acta 2002;1572(2-3):387-400
   Google Scholar
• Maeda K, Mehta H, Drevets DA, et al. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 2010;115(23):4699-706
   PubMed Web of Science ®Google Scholar
• Yan Y, Wang YH, Diamond B. IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells. J Autoimmun 2012;38(1):1-9
   Google Scholar
• Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48(4):971-81
   PubMedGoogle Scholar
• Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48(7):2052-8
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43(1):4-13
   PubMed Web of Science ®Google Scholar
• Murn J, Alibert O, Wu N, et al. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med 2008;205(13):3091-103
   PubMed Web of Science ®Google Scholar
• Prijatelj M, Celhar T, Mlinaric-Rascan I. Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells. Prostaglandins Other Lipid Mediat 2011;95(1-4):19-26
   Google Scholar
• Magari M, Nishikawa Y, Fujii Y, et al. IL-21-dependent B cell death driven by prostaglandin E2, a product secreted from follicular dendritic cells. J Immunol 2011;187(8):4210-18
   Google Scholar
• Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282(16):11613-17
   PubMed Web of Science ®Google Scholar
• McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002;110(5):651-8
   PubMed Web of Science ®Google Scholar
• Honda T, Segi-Nishida E, Miyachi Y, et al. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 2006;203(2):325-35
   Google Scholar
• Cantaert T, Teitsma C, Tak PP, et al. Presence and role of anti-citrullinated protein antibodies in experimental arthritis models. Arthritis Rheum 2013;65(4):939-48
   Google Scholar
• Kojima F, Frolov A, Matnani R, et al. Reduced T Cell-dependent humoral immune response in microsomal prostaglandin E synthase-1 null mice is mediated by nonhematopoietic cells. J Immunol 2013;191(10):4979-88
   Google Scholar
• Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008;28(1):18-28
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Chang PP. Innate B cell helpers reveal novel types of antibody responses. Nat Immunol 2013;14(2):119-26
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Brigl M, Illarionov P, et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci USA 2008;105(24):8339-44
   PubMed Web of Science ®Google Scholar
• Barral P, Eckl-Dorna J, Harwood NE, et al. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci USA 2008;105(24):8345-50
   PubMed Web of Science ®Google Scholar
• Chang PP, Barral P, Fitch J, et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol 2012;13(1):35-43
   Web of Science ®Google Scholar
• Puga I, Cols M, Barra CM, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 2012;13(2):170-80
   Google Scholar
• Mancardi DA, Jonsson F, Iannascoli B, et al. Cutting edge: the murine high-affinity IgG receptor FcgammaRIV is sufficient for autoantibody-induced arthritis. J Immunol 2011;186(4):1899-903
   PubMed Web of Science ®Google Scholar
• Laurent L, Clavel C, Lemaire O, et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011;70(6):1052-9
   PubMed Web of Science ®Google Scholar
• Spits H, Artis D, Colonna M, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol 2013;13(2):145-9
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Linterman MA, Goodnow CC, et al. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010;237(1):72-89
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012;491(7423):264-8
   PubMed Web of Science ®Google Scholar
• Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 2008;20(1):14-25
   PubMed Web of Science ®Google Scholar
• Heesters BA, Chatterjee P, Kim YA, et al. Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 2013;38(6):1164-75
   PubMed Web of Science ®Google Scholar
• Chappell CP, Draves KE, Giltiay NV, et al. Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp Med 2012;209(10):1825-40
   PubMedGoogle Scholar
• Gujer C, Sandgren KJ, Douagi I, et al. IFN-alpha produced by human plasmacytoid dendritic cells enhances T cell-dependent naive B cell differentiation. J Leukoc Biol 2011;89(6):811-21
   Google Scholar
• McGaha TL, Chen Y, Ravishankar B, et al. Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood 2011;117(20):5403-12
   Google Scholar
• Li H, Wu Q, Li J, et al. Cutting Edge: defective follicular exclusion of apoptotic antigens due to marginal zone macrophage defects in autoimmune BXD2 mice. J Immunol 2013;190(9):4465-9
   Google Scholar
• Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167(2):1072-80
   PubMed Web of Science ®Google Scholar
• Wengner AM, Hopken UE, Petrow PK, et al. CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum 2007;56(10):3271-83
   Google Scholar
• Yeo L, Toellner KM, Salmon M, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011;70(11):2022-8
   PubMed Web of Science ®Google Scholar
• Mansour A, Anginot A, Mancini SJ, et al. Osteoclast activity modulates B-cell development in the bone marrow. Cell Res 2011;21(7):1102-15
   Google Scholar
• Tokoyoda K, Egawa T, Sugiyama T, et al. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004;20(6):707-18
   PubMed Web of Science ®Google Scholar
• Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001;166(3):1482-91
   Google Scholar
• Zhu J, Garrett R, Jung Y, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 2007;109(9):3706-12
   PubMed Web of Science ®Google Scholar
• Tsubaki T, Takegawa S, Hanamoto H, et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 2005;141(2):363-71
   Google Scholar
• Rosengren S, Wei N, Kalunian KC, et al. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology 2011;50(3):603-10
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Kam NW, Brentano F, et al. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis 2011;70(10):1857-65
   Google Scholar
• Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174(2):864-70
   PubMedGoogle Scholar
• Nakayama T, Hieshima K, Izawa D, et al. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003;170(3):1136-40
   Google Scholar
• Mourcin F, Breton C, Tellier J, et al. Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood 2011;117(24):6552-61
   Google Scholar
• Anginot A, Espeli M, Chasson L, et al. Galectin 1 modulates plasma cell homeostasis and regulates the humoral immune response. J Immunol 2013;190(11):5526-33
   Google Scholar
• Bugatti S, Manzo A, Caporali R, et al. Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. Arthritis Res Ther 2012;14(6):229
   Google Scholar
• Chu VT, Frohlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011;12(2):151-9
   PubMed Web of Science ®Google Scholar
• Koble C, Kyewski B. The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J Exp Med 2009;206(7):1505-13
   Google Scholar
• Lukacs-Kornek V, Turley SJ. Self-antigen presentation by dendritic cells and lymphoid stroma and its implications for autoimmunity. Curr Opin Immunol 2011;23(1):138-45
   Google Scholar
• Manzo A, Bombardieri M, Humby F, et al. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010;233(1):267-85
   PubMedGoogle Scholar
• Weyand CM, Kang YM, Kurtin PJ, et al. The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr Opin Rheumatol 2003;15(3):259-66
   PubMed Web of Science ®Google Scholar
• Fujii W, Ashihara E, Hirai H, et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol 2013;191(3):1073-81
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806
   PubMed Web of Science ®Google Scholar
• Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010;107(10):4658-63
   Google Scholar
• Montalvao F, Garcia Z, Celli S, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013;123(12):5098-103
   PubMed Web of Science ®Google Scholar
• Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70(12):2119-25
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186(6):3762-9
   PubMed Web of Science ®Google Scholar
• Geng SS, Feng J, Li Y, et al. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange. Cell Mol Immunol 2006;3(6):439-43
   Google Scholar
• Hamel KM, Cao Y, Ashaye S, et al. B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol 2011;187(9):4900-6
   Google Scholar
• van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63(6):1507-16
   PubMedGoogle Scholar
• Gheorghe KR, Thurlings RM, Westman M, et al. Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression. PLoS One 2011;6(1):e16378
   Google Scholar
• Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):572-7
   PubMed Web of Science ®Google Scholar
• Mei HE, Schmidt S, Dorner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 2012;14(Suppl 5):S1
   PubMed Web of Science ®Google Scholar
• Chu SY, Yeter K, Kotha R, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor and FcgammaRIIb inhibitory receptor. Arthritis Rheum 2013. [Epub ahead of print]
   Google Scholar
• Moura RA, Canhao H, Polido-Pereira J, et al. BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. J Rheumatol 2013;40(8):1293-302
   Google Scholar
• Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 2013;72(9):1461-8
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63(7):1782-92
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 2013;40(5):579-89
   PubMed Web of Science ®Google Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14(7):748-55
   PubMed Web of Science ®Google Scholar
• Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67(4):1783-92
   PubMed Web of Science ®Google Scholar
• van der Heijden JW, Oerlemans R, Lems WF, et al. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009;27(1):92-8
   Google Scholar
• Yannaki E, Papadopoulou A, Athanasiou E, et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010;62(11):3277-88
   PubMedGoogle Scholar
• Lee SW, Kim JH, Park YB, et al. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009;68(11):1761-7
   Google Scholar
• Toubi E, Kessel A, Slobodin G, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(6):818-20
   Web of Science ®Google Scholar
• Bao Y, Liu X, Han C, et al. Identification of IFN-gamma-producing innate B cells. Cell Res 2014;24(2):161-76
   Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73(1):183-90
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8(4):R129
   PubMed Web of Science ®Google Scholar
• Bonelli M, Ferner E, Goschl L, et al. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum 2013;65(3):599-607
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69(1):88-96
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63(3):609-21
   PubMed Web of Science ®Google Scholar
• A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM). Available from: http://clinicaltrials.gov/show/NCT01710358
   Google Scholar
• Evaluation of efficacy and safety of fostamatinib monotherapy compared with adalimumab monotherapy in patients with rheumatoid arthritis (RA) (OSKIRA -4). Available from: http://clinicaltrials.gov/show/NCT01264770
   Google Scholar
• Liu L, Di Paolo J, Barbosa J, et al. Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther 2011;338(1):154-63
   PubMed Web of Science ®Google Scholar
• Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011;7(1):41-50
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122(15):2539-49
   PubMed Web of Science ®Google Scholar
• Bonami RH SA, Case JB, Hoek KL, et al. Bruton’s tyrosine kinase promotes persistence of mature anti-insulin B cells. J Immunol 2014;192(4):1459-70
   Google Scholar
• Thomas R. Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther 2013;15(1):204
   Google Scholar